X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LX2006 is an AAV-based gene therapy candidate & designed to deliver a functional frataxin gene. It is being evaluated for the treatment of friedreich’s ataxia cardiomyopathy.
Lead Product(s): LX2006
Therapeutic Area: Genetic Disease Product Name: LX2006
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Lexeo intends to use net proceeds to fund advancement of ongoing clinical stage programs, including LX2006, a gene therapy candidate designed to deliver a functional frataxin, or FXN, gene for the treatment of FA cardiomyopathy.
Lead Product(s): LX2006
Therapeutic Area: Genetic Disease Product Name: LX2006
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $95.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 13, 2024
Details:
Lexeo intends to use net proceeds to fund advancement of ongoing clinical stage programs, including LX2006, a gene therapy candidate designed to deliver a functional frataxin, or FXN, gene for the treatment of FA cardiomyopathy.
Lead Product(s): LX2006
Therapeutic Area: Genetic Disease Product Name: LX2006
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $95.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 11, 2024
Details:
LX2020 is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional PKP2 gene to cardiac muscle, which is under phase 1/2 clinical development for the treatment of arrhythmogenic cardiomyopathy (ACM) caused by mutations in the PKP2 gene (PKP2-ACM).
Lead Product(s): LX2020
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LX2020
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The proceeds will advance the development of LX2006, LX2020 and LX1001 and will fund the continued development of other programs and cardiac discovery efforts. LX2006 is an AAV-based gene therapy candidate delivered intravenously for the treatment of FA cardiomyopathy.
Lead Product(s): LX2006
Therapeutic Area: Genetic Disease Product Name: LX2006
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 02, 2023
Details:
In connection with this investment, the companies will explore the development of novel gene therapy candidates, including LX2021 and LX2022 for a range of cardiovascular diseases.
Lead Product(s): LX2021
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LX2021
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sarepta Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing August 28, 2023
Details:
LX2020 is designed to intravenously deliver a functional PKP2 gene to cardiac muscle to increase PKP2 protein levels in the cardiac desmosome, a cell structure critical for cell adhesion.
Lead Product(s): AAVrh10-based Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LX2020
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
LX2006 is an AAV-based gene therapy candidate delivered intravenously and designed to target the cardiac manifestations of FA by delivering a functional frataxin gene to promote the expression of the frataxin protein and restore mitochondrial function in myocardial cells.
Lead Product(s): LX2006
Therapeutic Area: Genetic Disease Product Name: LX2006
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
LX1001-01 (AAVrh.10hAPOE2) is an AAV-based investigational gene therapy candidate designed as a one-time treatment delivering a protective APOE2 gene into the CNS for the treatment of APOE4-associated Alzheimer’s disease.
Lead Product(s): AAVrh.10hAPOE2
Therapeutic Area: Neurology Product Name: LX1001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Cerveau Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 07, 2022
Details:
LX2006 (AAVrh.10hFXN) is an AAV-based gene therapy delivered intravenously for the treatment of FA cardiomyopathy and is designed to transfer the FXN gene to myocardial cells and increase frataxin levels in the mitochondria.
Lead Product(s): AAVrh.10hFXN
Therapeutic Area: Genetic Disease Product Name: LX2006
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
